Paul Glossop

Title: Paul Glossop: Inventor of a CK2α Inhibitor Patent

Introduction

Paul Glossop is an inventor associated with Cambridge, Great Britain, and Cambridge Enterprise Limited. His patent work concerns compounds designed to inhibit Casein Kinase 2 alpha (CK2α), a target implicated in several diseases and biological processes.

Latest Patents

Glossop is associated with 1 patent, titled “Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof.” The patent describes compounds and their salts, hydrates, and solvates that inhibit CK2α. It also covers pharmaceutical compositions, methods for synthesizing the compounds, and their potential therapeutic uses.

The disclosed compounds are proposed for treating or preventing conditions in which CK2α activity is implicated. These include proliferative disorders such as cancer, viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration, and conditions involving circadian-rhythm regulation.

Career Highlights

Glossop’s listed patent reflects work at the intersection of medicinal chemistry and therapeutic research. The invention focuses on developing CK2α inhibitors and describing their possible applications in disease treatment and prevention. He is associated with Cambridge Enterprise Limited.

Collaborations

The listed coworkers associated with Glossop include Marko Juhana Hyvonen and Paul Brear. Their names appear alongside the patent-related information provided for this profile.

Conclusion

Paul Glossop’s patent activity centers on CK2α-inhibiting compounds and their potential therapeutic applications, connecting his work with Cambridge Enterprise Limited and collaborators Marko Juhana Hyvonen and Paul Brear.